PURE Bioscience, Inc.
PURE
$0.0653
$0.00538.83%
OTC PK
| 01/31/2025 | 10/31/2024 | 07/31/2024 | 04/30/2024 | 01/31/2024 | |
|---|---|---|---|---|---|
| Revenue | 1.86M | 1.80M | 1.96M | 2.09M | 2.06M |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | 1.86M | 1.80M | 1.96M | 2.09M | 2.06M |
| Cost of Revenue | 777.00K | 762.00K | 811.00K | 893.00K | 921.00K |
| Gross Profit | 1.09M | 1.04M | 1.15M | 1.20M | 1.14M |
| SG&A Expenses | 3.60M | 3.79M | 3.98M | 4.10M | 4.10M |
| Depreciation & Amortization | -- | -- | -- | -- | -- |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | 4.67M | 4.84M | 5.09M | 5.29M | 5.32M |
| Operating Income | -2.81M | -3.05M | -3.13M | -3.20M | -3.26M |
| Income Before Tax | -3.10M | -3.30M | -3.35M | -3.63M | -3.65M |
| Income Tax Expenses | -- | -- | -- | -- | -- |
| Earnings from Continuing Operations | -3.10 | -3.30 | -3.35 | -3.63 | -3.65 |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | -3.10M | -3.30M | -3.35M | -3.63M | -3.65M |
| EBIT | -2.81M | -3.05M | -3.13M | -3.20M | -3.26M |
| EBITDA | -2.70M | -2.90M | -2.98M | -3.08M | -3.14M |
| EPS Basic | -0.03 | -0.03 | -0.03 | -0.03 | -0.03 |
| Normalized Basic EPS | -0.02 | -0.02 | -0.02 | -0.02 | -0.02 |
| EPS Diluted | -0.03 | -0.03 | -0.03 | -0.03 | -0.03 |
| Normalized Diluted EPS | -0.02 | -0.02 | -0.02 | -0.02 | -0.02 |
| Average Basic Shares Outstanding | 447.43M | 447.43M | 447.43M | 447.12M | 446.62M |
| Average Diluted Shares Outstanding | 447.43M | 447.43M | 447.43M | 447.12M | 446.62M |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |